As of 12:30 PM on the 16th, Seegene is trading at 232,100 KRW, up 3.16% from the previous day. The trading volume is 745,693 shares, which is 39.24% of the previous day's volume. Seegene is known as a developer, manufacturer, and seller of molecular diagnostic reagents.


On November 13, Shin Jae-hoon, a researcher at Hanwha Investment & Securities, announced a target price of 430,000 KRW for Seegene, stating, "Growth in sales of COVID-19 reagents and equipment. COVID-19 reagents recorded 216.4 billion KRW (+7.7% QoQ), equipment 43.6 billion KRW (+2.2% QoQ). Sales by diagnostic reagent segment: respiratory 226.5 billion KRW (+8.7% QoQ), sexually transmitted diseases/female diseases 7.4 billion KRW (+99.2% QoQ), HPV 2.8 billion KRW (+614.0% QoQ), others 46.5 billion KRW (+136.0% QoQ)."


Over the past five days, individual investors have net purchased 512,279 shares of Seegene, while foreigners and institutions have net sold 291,560 shares and 228,462 shares, respectively.



※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing